|
| |
Audit of Bladder Cancer Pathways |
| |
Name |
Position |
Date Agreed |
Date Completed Date |
|
| |
Mr Alan Paul |
NSSG Chair |
Jan 2009 |
Jul 2009 |
 |
| |
Mr Rob Webster |
YCN Board Chair |
Aug 2009 |
- |
|
| |
|
| |
To audit the diagnosis and treatment pathway for patients with muscle invasive bladder cancer across the Yorkshire Cancer Network.
There is a perception that the waiting time targets are masking the true picture of waits between diagnosis and radical treatment (cystectomy/radical radiotherapy). This is because TURBT can count as “first treatment” for the purposes of the targets.
|
| |
Radical Prostatectomies Audit |
| |
Name |
Position |
Date Agreed |
Date Completed Date |
|
| |
Mr Alan Paul |
NSSG Chair |
Jan 2009 |
Jul 2009 |
|
| |
Mr Rob Webster |
YCN Board Chair |
Aug 2009 |
- |
|
| |
|
| |
To review the management of prostate cancer patients undergoing radical prostatectomy in order to determine practice across the Network.
- To provide a baseline position against which future audits can be compared.
- To provide evidence for the current guidelines and introduce new ones agreed by the Group in the light of current practice and evidence from the literature.
- The results will be presented by each specialist MDT to the YCN Urology Network Site Specific Group which will suggest possible changes in practice.
|
| |
An audit of the presentation of patients with testicular germ cell tumours |
| |
Name |
Position |
Date Agreed |
Date Completed Date |
|
| |
Mr Alan Paul |
NSSG Chair |
Oct 2009 |
Jul 2010 |
|
| |
Mr Rob Webster |
YCN Board Chair |
Sep 2010 |
- |
|
| |
|
| |
Some testicular cancer has a fast growth rate so early diagnosis and treatment is important.
YCN guidelines on testicular tumour are influenced by national frameworks for all cancers- in Yorkshire we have adapted those for the urgency.
Most patients will present to GP with testicular lump.
Patients referred by GP for ultrasound or to urology.
Primary surgery is not the best management for most cases of advanced disease - need CXR, markers and clinical examination to decide.
|
| |
T1 G3 Bladder Cancer Audit |
| |
Name |
Position |
Date Agreed |
Date Completed Date |
|
| |
Mr Alan Paul |
NSSG Chair |
Feb 2010 |
- |
|
| |
Mr Rob Webster |
YCN Board Chair |
Sep 2010 |
- |
|
| |
|
| |
- To identify any delays in the YCN bladder cancer pathway (non muscle invasive disease)
- To identify areas where less than ideal treatment is being undertaken, according to NICE Improving Outcome Guidance/ BAUS Guidelines
- To map the use of BCG maintenance in the YCN
|
